Australia, cloning and abortion drug mifepristone examined

NewsGuard 100/100 Score

The New York Times on Tuesday examined the political debates in Australia over the legalization earlier this year of the medical abortion drug mifepristone and whether to pass legislation that would legalize some forms of cloning of human embryos for therapeutic purposes.

According to the Times, Australians often are divided on so-called "values" issues, but political debates on such issues "do not degenerate into personal attacks" as they sometimes do in the U.S.

In addition, political candidates in Australia are "not concerned with playing to religious groups," and the political climate has led to Australian politicians having "candid debates on very emotional subjects," the Times reports.

The Australian Parliament in 2002 banned all types of cloning but called for a review of the ban after three years, and in 2005 a government-appointed committee recommended that therapeutic cloning be legalized.

The Australian Senate, after a recent "intense and emotional" debate, passed legislation by a 34-32 vote that would allow some forms of therapeutic cloning, according to the Times.

The Australian House is expected to pass the cloning legislation next month (Bonner, New York Times, 11/22).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tailoring online contraception education for culturally diverse women improves uptake and reduces unintended pregnancies